Abstract: Nebulized lidocaine appears promising as a novel corticosteroid-sparing therapeutic for equine asthma, but its safety and pharmacokinetic behavior have yet to be confirmed. Unassigned: To describe the effect of nebulized lidocaine on upper airway sensitivity, lung mechanics, and lower respiratory cellular response of healthy horses, as well as delivery of lidocaine to lower airways, and its subsequent absorption, clearance, and duration of detectability. Unassigned: Six healthy university- and client-owned horses with normal physical examination and serum amyloid A, and no history of respiratory disease within 6 months. Unassigned: Prospective, descriptive study evaluating the immediate effects of 1 mg/kg 4% preservative-free lidocaine following nebulization with the Flexineb®. Prior to and following nebulization, horses were assessed using upper airway endoscopy, bronchoalveolar lavage, and pulmonary function testing with esophageal balloon/pneumotachography and histamine bronchoprovocation. Additionally, blood and urine were collected at predetermined times following single-dose intravenous and nebulized lidocaine administration for pharmacokinetic analysis. Unassigned: Upper airway sensitivity was unchanged following lidocaine nebulization, and no laryngospasm or excessive salivation was noted. Lidocaine nebulization (1 mg/kg) resulted in a mean epithelial lining fluid concentration of 9.63 ± 5.05 μg/mL, and a bioavailability of 29.7 ± 7.76%. Lidocaine concentrations were higher in epithelial lining fluid than in systemic circulation (Cmax 149.23 ± 78.74 μg/L, CELF:Cmaxplasma 64.4, range 26.5-136.8). Serum and urine lidocaine levels remained detectable for 24 and 48 h, respectively, following nebulization of a single dose. Baseline spirometry, lung resistance and dynamic compliance, remained normal following lidocaine nebulization, with resistance decreasing post-nebulization. Compared to the pre-nebulization group, two additional horses were hyperresponsive following lidocaine nebulization. There was a significant increase in mean airway responsiveness post-lidocaine nebulization, based on lung resistance, but not dynamic compliance. One horse had BAL cytology consistent with airway inflammation both before and after lidocaine treatment. Unassigned: Nebulized lidocaine was not associated with adverse effects on upper airway sensitivity or BAL cytology. While baseline lung resistance was unchanged, increased airway reactivity to histamine bronchoprovocation in the absence of clinical signs was seen in some horses following nebulization. Further research is necessary to evaluate drug delivery, adverse events, and efficacy in asthmatic horses.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This research article studies the effects and pharmacokinetics of nebulized lidocaine in healthy horses. The study aims to establish its potential as a novel, steroid-sparing therapy for equine asthma and to understand its safety and pharmacokinetics.
Research Design and Methodology
The study was a prospective, descriptive one involving six healthy university- and client-owned horses that had no history of respiratory disease within the past six months.
The horses were administered 1 mg/kg of 4% preservative-free lidocaine through nebulization using the Flexineb device.
Prior to and after the nebulization, the horses underwent various examinations including upper airway endoscopy, bronchoalveolar lavage (BAL), and pulmonary function testing with esophageal balloon/pneumotachography and histamine bronchoprovocation.
For pharmacokinetic analysis, blood and urine samples were collected at predetermined times following single-dose intravenous and nebulized lidocaine administration.
Results and Findings
Nebulized lidocaine did not change upper airway sensitivity and it was not associated with laryngospasm or excessive salivation.
Lidocaine nebulization resulted in a mean epithelial lining fluid concentration of 9.63 ± 5.05 μg/mL, with a bioavailability of 29.7 ± 7.76%.
Lidocaine concentrations were higher in the epithelial lining fluid than in the systemic circulation, hinting at local delivery and absorption of the drug.
After nebulization, detectable levels of serum and urine lidocaine were present for 24 and 48 hours respectively.
Lung resistance and dynamic compliance remained normal following lidocaine nebulization, with resistance actually decreasing post-nebulization. However, airway responsiveness to histamine bronchoprovocation increased in some horses after nebulization.
One horse showed signs of airway inflammation both before and after lidocaine treatment, as assessed by BAL cytology.
Conclusion
The study concludes that nebulized lidocaine did not have adverse effects on upper airway sensitivity or BAL cytology.
However, there was an increase in airway reactivity to histamine bronchoprovocation in some horses following nebulization, even though clinical signs of inflammation were not apparent.
With these findings, the researchers suggest that further research is needed to evaluate drug delivery, potential adverse events, and the efficacy of nebulized lidocaine in asthmatic horses.
Cite This Article
APA
Minuto J, Bedenice D, Ceresia M, Zaghloul I, Böhlke M, Mazan MR.
(2022).
Clinical effects and pharmacokinetics of nebulized lidocaine in healthy horses.
Front Vet Sci, 9, 984108.
https://doi.org/10.3389/fvets.2022.984108
Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, United States.
Bedenice, Daniela
Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, United States.
Ceresia, Michelle
Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, United States.
Department of Pharmacy Practice, School of Pharmacy, MCPHS University, Boston, MA, United States.
Zaghloul, Iman
Department of Pharmaceutical Sciences, School of Pharmacy, MCPHS University, Boston, MA, United States.
Böhlke, Mark
Department of Pharmaceutical Sciences, School of Pharmacy, MCPHS University, Boston, MA, United States.
Mazan, Melissa R
Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, United States.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
This article includes 59 references
. Uniform Classification Guidelines for Foreign Substances and Recommended Penalties Model Rule. V.14.3. (2020).
Hermanns H, Hollmann MW, Stevens MF, Lirk P, Brandenburger T, Piegeler T. Molecular mechanisms of action of systemic lidocaine in acute and chronic pain: a narrative review. Br J Anaesth (2019) 123:335–49.
Abdulqawi R, Satia I, Kanemitsu Y, Khalid S, Holt K, Dockry R. A randomized controlled trial to assess the effect of lidocaine administered via throat spray and nebulization in patients with refractory chronic cough. J Allergy Clin Immunol Pract (2021) 9:1640–7.
Carvalho KIM, Coutinho DS, Joca HC, Miranda AS, Cruz JDS, Silva ET. Anti-bronchospasmodic effect of JME-173, a novel mexiletine analog endowed with highly attenuated anesthetic activity. Front Pharmacol (2020) 11:1159.
Lim KG, Rank MA, Hahn PY, Keogh KA, Morgenthaler TI, Olson EJ. Long-term safety of nebulized lidocaine for adults with difficult-to-control chronic cough: a case series. Chest (2013) 143:1060–5.
Ohnishi T, Kita H, Mayeno AN, Okada S, Sur S, Broide DH. Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. Clin Exp Immunol (1996) 104:325–31.
Okada S, Hagan JB, Kato M, Bankers-Fulbright JL, Hunt LW, Gleich GJ. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J Immunol (1998) 160:4010–7.
Molassiotis A, Bryan G, Caress A, Bailey C, Smith J. Pharmacological and non-pharmacological interventions for cough in adults with respiratory and non-respiratory diseases: A systematic review of the literature. Respir Med (2010) 104:934–44.
Slaton RM, Thomas RH, Mbathi JW. Evidence for therapeutic uses of nebulized lidocaine in the treatment of intractable cough and asthma. Ann Pharmacother (2013) 47:578–85.
Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol (1985) 60:532–8.
Pocino K, Minucci A, Manieri R, Conti G, De Luca D, Capoluongo ED. Description of an automated method for urea nitrogen determination in bronchoalveolar lavage fluid (BALF) of neonates and infants. J Lab Autom (2015) 20:636–41.
Almasry IO, Tschaubrunn CM. Antiarrhythmic electrophysiology and pharmacotherapy. In Jeremias A, Brown DL, editors. Cardiac Intensive Care. 2 ed. W.B. Saunders; (2010).
Enright PL, McNally JF, Souhrada JF. Effect of lidocaine on the ventilatory and airway responses to exercise in asthmatics. Am Rev Respir Dis (1980) 122:823–8.
Kim JS, Kim DH, Joe HB, Oh CK, Kim JY. Effect of tracheal lidocaine on intubating conditions during propofol-remifentanil target-controlled infusion without neuromuscular blockade in day-case anesthesia. Korean J Anesthesiol (2013) 65:425–30.
Jones TL, Boyer K, Chapman K, Craigen B, da Cunha A, Hofmeister EH. Evaluation of the time to desensitization of the larynx of cats following topical lidocaine application. J Feline Med Surg (2021) 23:563–7.
Gerber V, Lindberg A, Berney C, Robinson NE. Airway mucus in recurrent airway obstruction–short-term response to environmental challenge. J Vet Intern Med (2004) 18:92–7.
Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Pharmacol Toxicol (1999) 84:143–6.
Stephens RH, Benjamin AR, Walters DV. Volume and protein concentration of epithelial lining liquid in perfused in situ postnatal sheep lungs. J Appl Physiol (1985) 80:1911–20.
Groeben H, Grosswendt T, Silvanus MT, Pavlakovic G, Peters J. Airway anesthesia alone does not explain attenuation of histamine-induced bronchospasm by local anesthetics: a comparison of lidocaine, ropivacaine, and dyclonine. Anesthesiology (2001) 94:423–8.
Groeben H, Silvanus MT, Beste M, Peters J. Both intravenous and inhaled lidocaine attenuate reflex bronchoconstriction but at different plasma concentrations. Am J Respir Crit Care Med (1999) 159:530–5.
Groeben H, Silvanus MT, Beste M, Peters J. Lidocaine inhalation for local anaesthesia and attenuation of bronchial hyper-reactivity with least airway irritation. Effect of three different dose regimens. Eur J Anaesthesiol (2000) 17:672–9.
Groeben H, Silvanus MT, Beste M, Peters J. Combined lidocaine and salbutamol inhalation for airway anesthesia markedly protects against reflex bronchoconstriction. Chest (2000) 118:509–15.
Muraki M, Iwanaga T, Haraguchi R, Kubo H, Tohda Y. Continued inhalation of lidocaine suppresses antigen-induced airway hyperreactivity and airway inflammation in ovalbumin-sensitized guinea pigs. Int Immunopharmacol (2008) 8:725–31.
Baser Y, deShazo RD, Barkman HW Jr., Nordberg J. Lidocaine effects on immunocompetent cells. Implications for studies of cells obtained by bronchoalveolar lavage. Chest (1982) 82:323–8.
Yu YM, Long YZ, Zhu ZQ. Chitosan, a Natural Polymer, is an Excellent Sustained-Release Carrier for Amide Local Anesthetics. J Pain Res 2024;17:3539-3551.